Author:
Rosé Mathieu,Bourahla Intissar,Ghiddi Alessandro,Al-Akabawi Assem,Chan Edmond,Toussi Massoud
Funder
Janssen-Cilag International NV
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference19 articles.
1. Agyemang E, Bailey L, Talbot J. Additional risk minimisation measures for medicinal products in the European Union: a review of the implementation and effectiveness of measures in the United Kingdom by one marketing authorisation holder. Pharmaceut Med. 2017;31(2):101–12.
2. Landsberg W, Al-Dakkak I, Coppin-Renz A, et al. Effectiveness evaluation of additional risk minimization measures for adolescent use of aripiprazole in the European Union: results from a post-authorization safety study. Drug Saf. 2018;41(8):797–806.
3. Felo L, Otero-Lobato M, Geldhof A, Noël W. Effectiveness of the golimumab educational program in ensuring healthcare professionals’ awareness of risks described in the European risk management plan. Ther Adv Drug Saf. 2019;10:2042098619847420.
4. Lem J, Younus M, Aram JA, et al. Evaluation of the effectiveness of additional risk minimization measures for voriconazole in the EU: findings and lessons learned from a healthcare professional survey. Pharmaceut Med. 2019;33(2):121–33.
5. Janssen Biotech Inc. Darzalex (daratumumab) [package insert]. Revised September 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761036s024lbl.pdf. Accessed 10 Jan 2020.